AGILE THERAPEUTICS INC
AGILE THERAPEUTICS INC (AGRX): 6 pipeline candidates · ~3 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.8 months
D/E -1.68 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for AGILE THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$2.8M
Quarterly Burn
$6.8M
Runway
2.8 mo
Revenue
$5.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| ag200-15 er smp | Preclinical |
| ag200-15 extended regimen | Preclinical |
| ag200-15 smp | Preclinical |
| agle-102 | Phase 1/Phase 2 |
| cromolyn | Approved |
| twirla | Approved |
Frequently asked questions
How many drug candidates are in AGILE THERAPEUTICS INC's pipeline?
AGILE THERAPEUTICS INC (AGRX) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AGILE THERAPEUTICS INC's lead drug candidate?
AGILE THERAPEUTICS INC's most advanced tracked candidate is ag200-15 er smp (Preclinical) for contraception.
What is AGILE THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AGILE THERAPEUTICS INC has approximately 2.8 months of cash runway.
Get the full picture on AGILE THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.